NYSE:PBH

Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

$71.56
+1.06 (+1.50%)
(As of 01:31 PM ET)
Today's Range
$70.89
$71.56
50-Day Range
$68.03
$75.15
52-Week Range
$55.96
$75.31
Volume
69,982 shs
Average Volume
231,443 shs
Market Capitalization
$3.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.00

Prestige Consumer Healthcare MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
53.7% Upside
$110.00 Price Target
Short Interest
Bearish
3.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.80mentions of Prestige Consumer Healthcare in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$12,112 Sold Last Quarter
Proj. Earnings Growth
6.47%
From $4.33 to $4.61 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

588th out of 2,771 stocks

Pharmaceutical Preparations Industry

245th out of 1,288 stocks

PBH stock logo

About Prestige Consumer Healthcare Stock (NYSE:PBH)

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

PBH Stock Price History

PBH Stock News Headlines

Prestige Consumer Healthcare (PBH) to Release Earnings on Tuesday
Prestige Consumer Healthcare Inc.
PBH Mar 2024 55.000 put
PBH Jul 2024 70.000 call
Prestige Consumer Healthcare: Fiscal Q3 Earnings Snapshot
See More Headlines
Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
5/14/2024
Next Earnings (Confirmed)
5/14/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
CUSIP
74112D10
Employees
560
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$110.00
High Stock Price Target
$117.00
Low Stock Price Target
$103.00
Potential Upside/Downside
+53.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-82,310,000.00
Pretax Margin
-8.01%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.09 per share
Book Value
$29.12 per share

Miscellaneous

Free Float
48,855,000
Market Cap
$3.55 billion
Optionable
Optionable
Beta
0.53
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


PBH Stock Analysis - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PBH shares.
View PBH analyst ratings
or view top-rated stocks.

What is Prestige Consumer Healthcare's stock price target for 2024?

2 brokers have issued 1-year target prices for Prestige Consumer Healthcare's shares. Their PBH share price targets range from $103.00 to $117.00. On average, they anticipate the company's share price to reach $110.00 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price.
View analysts price targets for PBH
or view top-rated stocks among Wall Street analysts.

How have PBH shares performed in 2024?

Prestige Consumer Healthcare's stock was trading at $61.22 at the start of the year. Since then, PBH stock has increased by 16.9% and is now trading at $71.56.
View the best growth stocks for 2024 here
.

When is Prestige Consumer Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PBH earnings forecast
.

How can I listen to Prestige Consumer Healthcare's earnings call?

Prestige Consumer Healthcare will be holding an earnings conference call on Wednesday, May 15th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) issued its quarterly earnings data on Thursday, February, 8th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.02. The business earned $282.74 million during the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 14.09%. Prestige Consumer Healthcare's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.04 earnings per share.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.57%), Allspring Global Investments Holdings LLC (2.11%), Allspring Global Investments Holdings LLC (2.11%), Congress Asset Management Co. MA (1.54%), Rice Hall James & Associates LLC (1.27%) and Nordea Investment Management AB (1.16%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends
.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PBH) was last updated on 5/14/2024 by MarketBeat.com Staff

From Our Partners